How Doctors Choose Parkinson's Medications

This is an archived file of a live webcast that took place on September 15, 2016.

In this webinar, our panelists discuss how doctors and patients work together to choose what medications to start, adjust or discontinue. We also answer common medication questions, including "When should one start levodopa?" and "What does prescribing off label mean?"

Title: How Doctors Choose Parkinson's Medications

Duration: 1 hour

Continuing Medical Education Information for Health Care Professionals

MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: September 15, 2016
Date CME Credit No Longer Available: September 15, 2018

Learning Objectives
At the conclusion of this course, participants should be able to:

  1. Describe how medications are selected and adjusted to manage Parkinson's motor and non-motor symptoms.
  2. Discuss the pros and cons of levodopa therapy, including early vs. later initiation.
  3. Recognize best practices in starting and discontinuing Parkinson's medications.
  4. Define "off label" prescribing.

Target Audience
This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Dave Iverson
Nothing to disclose

Thomas L. Davis, MD
Professor of Neurology
Director, Division of Movement Disorders
Vanderbilt University Medical Center
Disclosures: AbbVie Pharmaceuticals
Rachel Dolhun, MD
Vice President, Medical Communications
The Michael J. Fox Foundation
No disclosures


Already Registered?

*Required Fields.

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.

By registering you agree to receive email updates from
The Michael J. Fox Foundation. You can unsubscribe any time.